T-Cell Immunosuppressive Agent (Ophthalmic Drug)

Prescriber Highlights

  • Ophthalmic ointment for treatment of keratoconjunctivitis sicca (KCS) and other inflammatory ocular diseases 
  • Normal tear production requires weeks of therapy with cyclosporine; however, treatment cessation results in loss of tear production within days
  • Patients that do not respond to approved ophthalmic ointment may benefit from higher concentrations of cyclosporine compounded as an ophthalmic solution
Related Articles

Sign in to continue reading this article

Not registered? Create an account for free to read full articles on www.veterinaryteambrief.com.

To access full articles on www.veterinaryteambrief.com, please sign in below.

Busy? Sign in Faster. Sign into www.veterinaryteambrief.com with your social media account.